FHI Clinical Inc. has announced that it has a subcontract with the Frederick National Laboratory for Cancer Research to provide clinical operations services for the Adaptive COVID-19 Treatment Trial (ACTT), a study to allow investigation of putative therapeutics, for the treatment of COVID-19 in hospitalized adults. The first iteration, from ACTT-1, included 1,063 participants recruited within an eight-week period at 60 study sites and 13 subsites from places like in Denmark, Germany, Japan, Korea, Singapore, the United States, and more. ACTT-2 is now open.
For more information, click here.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access